Stock Code: 300765
Stock Abbreviation: CSPC Pharmaceutical Innovation
Announcement Number: 2026-062
CSPC Pharmaceutical Innovation Co., Ltd.
Announcement on the Signing of a Cooperation, Option, and License Agreement between the Controlling Subsidiary and AstraZeneca
The Company and the entire Board of Directors guarantee that the information disclosed is true, accurate, and complete, and contains no false statements, misleading representations, or material omissions.
I. Transaction Overview
CSPC Pharmaceutical Innovation Co., Ltd. (hereinafter referred to as the "Company")'s controlling subsidiary, CSPC Group Giant Biologics Co., Ltd. (hereinafter referred to as "Giant Biologics"), signed the "Cooperation, Option, and License Agreement" with AstraZeneca on July 1, 2026. The agreement establishes a strategic partnership with AstraZeneca in the field of novel extracellularly delivered small interfering RNA (siRNA) drug candidates (hereinafter referred to as the "Transaction"), focusing on the development of novel extracellularly delivered siRNA drug candidates.
II. Basic Information of the Counterparty
The counterparty to this transaction is AstraZeneca. AstraZeneca is a leading global biopharmaceutical company with extensive experience in the research, development, and commercialization of biologics and pharmaceuticals. AstraZeneca has no affiliation with the Company.